Medication effects on sleep and breathing

Clinics in Chest Medicine

Volumn 35, Issue 3, 2014, Pages 557-569

  Seda, Gilbert ^a   Tsai, Sheila ^b   Lee Chiong, Teofilo ^c  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Antipsychotics; Benzodiazepines; Central sleep apnea; Estrogen; Hypnotics; Obstructive sleep apnea; Progesterone; Testosterone

Indexed keywords

ACETAZOLAMIDE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ARMODAFINIL; BENZODIAZEPINE; CARBON DIOXIDE; CLONAZEPAM; CORTICOSTEROID; DIPHENHYDRAMINE; ESZOPICLONE; FLURAZEPAM; GABAPENTIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHADONE; MODAFINIL; NALOXONE; NARCOTIC AGENT; OXYBATE SODIUM; OXYGEN; PHENTERMINE; PLACEBO; PREGABALIN; PROMETHAZINE; RAMELTEON; TEMAZEPAM; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM;

AGING; ALTITUDE; ALTITUDE DISEASE; APNEA; APNEA HYPOPNEA INDEX; ASTHMA; BEHAVIOR DISORDER; BLOOD CARBON DIOXIDE TENSION; BLOOD OXYGEN TENSION; BREATHING DISORDER; BREATHING MECHANICS; BREATHING MUSCLE; CATAPLEXY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DAYTIME SOMNOLENCE; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG OVERDOSE; ENDOCRINE FUNCTION; FOCAL EPILEPSY; HUMAN; HYPERCAPNIA; HYPERSOMNIA; HYPOVENTILATION; HYPOXEMIA; HYPOXIA; INSOMNIA; LOW DRUG DOSE; LUNG VENTILATION; MUSCLE TONE; NARCOLEPSY; NEUROPATHIC PAIN; PATIENT COMPLIANCE; POLYPHARMACY; POSITIVE END EXPIRATORY PRESSURE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REM SLEEP; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP STAGE;

ANTIPSYCHOTICS; BENZODIAZEPINES; CENTRAL SLEEP APNEA; ESTROGEN; HYPNOTICS; OBSTRUCTIVE SLEEP APNEA; PROGESTERONE; TESTOSTERONE;

ACETAZOLAMIDE; ALTITUDE; ANDROGENS; ANOXIA; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; HYPERCAPNIA; HYPNOTICS AND SEDATIVES; PHOSPHODIESTERASE INHIBITORS; RESPIRATION; SLEEP; SLEEP APNEA, OBSTRUCTIVE; SLEEP, REM; TESTOSTERONE; THEOPHYLLINE;

EID: 84906789868     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2014.06.011     Document Type: Review

References (137)

1. Pever J.H., Sessle B.J. Sensory and motor processes during sleep and wakefulness. Principles and Practice of Sleep Medicine 2010, 348-359. Saunders, Missouri. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
2. Douglas N.J., White D.P., Weil J.V., et al. Hypercapnic ventilatory response in sleeping adults. Am Rev Respir Dis 1982, 126(5):758-762.
3. San T., Polat S., Cingi C., et al. Effects of high altitude on sleep and respiratory system and theirs adaptations. ScientificWorldJournal 2013, 2013:241569.
4. Stradling J.R., Chadwick G.A., Frew A.J. Changes in ventilation and its components in normal subjects during sleep. Thorax 1985, 40(5):364-370.
5. Douglas N.J., White D.P., Pickett C.K., et al. Respiration during sleep in normal man. Thorax 1982, 37:840-844.
6. Ioachimescu O.C., Collop N.A. Sleep-disordered breathing. Neurol Clin 2012, 30:1095-1136.
7. Lee-Chiong T. Somnology 2: Learn sleep medicine in one weekend. CreateSpace Independent Publishing Platform; 2011. p. 17.
8. Roux F.J., Kryger M.H. Medication effects on sleep. Clin Chest Med 2010, 31(2):397-405.
9. Stege G., Heijdra Y.F., van den Elshout F.J., et al. Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med 2010, 104(4):518-524.
10. Timms R.M., Dawson A., Hajdukovic R.M., et al. Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease. Arch Intern Med 1988, 148(10):2159-2163.
11. Wang D., Marshall N.S., Duffin J., et al. Phenotyping interindividual variability in obstructive sleep apnoea response to temazepam using ventilatory chemoreflexes during wakefulness. JSleep Res 2011, 20(4):526-532.
12. Dubowitz G. Effect of temazepam on oxygen saturation and sleep quality at high altitude: randomised placebo controlled crossover trial. BMJ 1998, 316(7131):587-589.
13. Nickol A.H., Leverment J., Richards P., et al. Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study. JSleep Res 2006, 15(4):445-454.
14. Röggla G., Moser B., Röggla M. Effect of temazepam on ventilatory response at moderate altitude. BMJ 2000, 320(7226):56.
15. Guilleminault C. Benzodiazepines, breathing, and sleep. Am J Med 1990, 88(3A):25S-28S.
16. Dolly F.R., Block A.J. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic subjects. Am J Med 1982, 73(2):239-243.
17. Block A.J., Wynne J.W., Boysen P.G. Sleep-disordered breathing and nocturnal oxygen desaturation in postmenopausal women. Am J Med 1980, 69(1):75-79.
18. Cummiskey J., Guilleminault C., Del Rio G., et al. The effects of flurazepam on sleep studies in patients with chronic obstructive pulmonary disease. Chest 1983, 84(2):143-147.
19. Genta P.R., Eckert D.J., Gregorio M.G., et al. Critical closing pressure during midazolam-induced sleep. JAppl Physiol (1985) 2011, 111(5):1315-1322.
20. Collen J., Lettieri C., Kelly W., et al. Clinical and polysomnographic predictors of short-term continuous positive airway pressure compliance. Chest 2009, 135(3):704-709.
21. Eckert D.J., Owens R.L., Kehlmann G.B., et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci (Lond) 2011, 120(12):505-514.
22. Rosenberg R., Roach J.M., Scharf M., et al. Apilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med 2007, 8(5):464-470.
23. Lettieri C.J., Quast T.N., Eliasson A.H., et al. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial. Sleep 2008, 31(9):1310-1316.
24. Coyle M.A., Mendelson W.B., Derchak P.A., et al. Ventilatory safety of zaleplon during sleep in patients with obstructive sleep apnea on continuous positive airway pressure. JClin Sleep Med 2005, 1(1):97.
25. Steens R.D., Pouliot Z., Millar T.W., et al. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993, 16(4):318-326.
26. Quadri S., Drake C., Hudgel D.W. Improvement of idiopathic central sleep apnea with zolpidem. JClin Sleep Med 2009, 5(2):122-129.
27. Beaumont M., Batéjat D., Coste O., et al. Effects of zolpidem and zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4,000 m. Neuropsychobiology 2004, 49(3):154-162.
28. Beaumont M., Batéjat D., Piérard C., et al. Zaleplon and zolpidem objectively alleviate sleep disturbances in mountaineers at a 3,613 meter altitude. Sleep 2007, 30(11):1527-1533.
29. Girault C., Muir J.F., Mihaltan F., et al. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Chest 1996, 110(5):1203-1211.
30. Kryger M., Wang-Weigand S., Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath 2007, 11(3):159-164.
31. Kryger M., Wang-Weigand S., Zhang J., et al. Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath 2008, 12(3):243-250.
32. Kryger M., Roth T., Wang-Weigand S., et al. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath 2009, 13(1):79-84.
33. Yue H.J., Guilleminault C. Opioid medication and sleep-disordered breathing. Med Clin North Am 2010, 94(3):435-446.
34. Drummond G.B. Comparison of decreases in ventilation caused by enflurane and fentanyl during anaesthesia. Br J Anaesth 1984, 55:825-835.
35. Weil J.V., McCullough R.E., Kline J.S., et al. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. NEngl J Med 1975, 292:1103-1106.
36. Farney R.J., Walker J.M., Cloward T.V., et al. Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003, 123(2):632-639.
37. Sharkey K.M., Kurth M.E., Anderson B.J., et al. Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints. Drug Alcohol Depend 2010, 108(1-2):77-83.
38. Teichtahl H., Wang D., Cunnington D., et al. Ventilatory responses to hypoxia and hypercapnia in stable methadone maintenance treatment patients. Chest 2005, 128(3):1339-1347.
39. Meurice J.C., Marc I., Sériès F. Effects of naloxone on upper airway collapsibility in normal sleeping subjects. Thorax 1996, 51(8):851-852.
40. Atkinson R.L., Suratt P.M., Wilhoit S.C., et al. Naloxone improves sleep apnea in obese humans. Int J Obes 1985, 9(4):233-239.
41. Ferber C., Duclaux R., Mouret J. Naltrexone improves blood gas patterns in obstructive sleep apnoea syndrome through its influence on sleep. JSleep Res 1993, 2(3):149-155.
42. Kalpaklioglu F., Baccioglu A. Efficacy and safety of H1-antihistamines: an update. Antiinflamm Antiallergy Agents Med Chem 2012, 11(3):230-237.
43. Krystal A.D., Durrence H.H., Scharf M., et al. Efficacy and safety of Doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010, 33(11):1553-1561.
44. Krystal A.D., Lankford A., Durrence H.H., et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011, 34(10):1433-1442.
45. Roth T., Rogowski R., Hull S., et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007, 30(11):1555-1561.
46. Roth T., Heith Durrence H., Jochelson P., et al. Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med 2010, 11(9):843-847.
47. Lankford A., Rogowski R., Essink B., et al. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012, 13(2):133-138.
48. McKelvey G.M., Post E.J., Jeffery H.E., et al. Sedation with promethazine profoundly affects spontaneous airway protection in sleeping neonatal piglets. Clin Exp Pharmacol Physiol 1999, 26(11):920-926.
49. Alexander C.M., Seifert H.A., Blouin R.T., et al. Diphenhydramine enhances the interaction of hypercapnic and hypoxic ventilatory drive. Anesthesiology 1994, 80(4):789-795.
50. Babenco H.D., Blouin R.T., Conard P.F., et al. Diphenylhydramine increases ventilatory drive during alfentanil infusion. Anesthesiology 1998, 89(3):642-647.
51. Regan W.M., Gordon S.M. Gabapentin for behavioral agitation in Alzheimer's disease. JClin Psychopharmacol 1997, 17:59-60.
52. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the management of postherpetic neuralgia: a randomized controlled trial. JAMA 1998, 280:1837-1842.
53. Garcia-Borreguero D., Kohnen R., Silber M.H., et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013, 14(7):675-684.
54. Batoon S.B., Vela A.T., Dave D., et al. Recurrent hypoventilation and respiratory failure during gabapentin therapy. JAm Geriatr Soc 2001, 49(4):498.
55. Català Pérez R., Gámez Lechuga M., Martínez-Lage Alvarez M., et al. Gabapentin-induced central hypoventilation. Med Clin (Barc) 2007, 128(13):519. [in Spanish].
56. Eipe N., Penning J. Postoperative respiratory depression with pregabalin: a case series and a preoperative decision algorithm. Pain Res Manag 2011, 16(5):353-356.
57. Hartley S., Quera-Salva M.A., Machou M. Sodium oxybate and sleep apnea: a clinical case. JClin Sleep Med 2011, 7(6):667-668.
58. Frase L., Schupp J., Sorichter S., et al. Sodium oxybate-induced central sleep apneas. Sleep Med 2013, 14(9):922-924.
59. Zvosec D.L., Smith S.W., Hall B.J. Three deaths associated with use of Xyrem. Sleep Med 2009, 10(4):490-493.
60. Inoue Y., Takasaki Y., Yamashiro Y. Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. JClin Sleep Med 2013, 9(8):751-757.
61. Roth T., White D., Schmidt-Nowara W., et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006, 28(5):689-706.
62. Winslow D.H., Bowden C.H., DiDonato K.P., et al. Arandomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012, 35(11):1529-1539.
63. Brownell L.G., Perez-Padilla R., West P., et al. The role of protriptyline in obstructive sleep apnea. Bull Eur Physiopathol Respir 1983, 19(6):621-624.
64. Smith P.L., Haponik E.F., Allen R.P., et al. The effects of protriptyline in sleep-disordered breathing. Am Rev Respir Dis 1983, 127(1):8-13.
65. Hanzel D.A., Proia N.G., Hudgel D.W. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991, 100(2):416-421.
66. Bart Sangal R., Sangal J.M., Thorp K. Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness. Sleep Med 2008, 9(5):506-510.
67. Carley D.W., Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med 1999, 160(6):1824-1829.
68. Carley D.W., Olopade C., Ruigt G.S., et al. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 2007, 30(1):35-41.
69. Marshall N.S., Yee B.J., Desai A.V., et al. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep 2008, 31(6):824-831.
70. Kraiczi H., Hedner J., Dahlöf P., et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999, 22(1):61-67.
71. Berry R.B., Yamaura E.M., Gill K., et al. Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep 1999, 22(8):1087-1092.
72. Winkelman J.W. Schizophrenia, obesity, and obstructive sleep apnea. JClin Psychiatry 2001, 62(1):8-11.
73. Rishi M.A., Shetty M., Wolff A., et al. Atypical antipsychotic medications are independently associated with severe obstructive sleep apnea. Clin Neuropharmacol 2010, 33(3):109-113.
74. Shirani A., Paradiso S., Dyken M.E. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. Sleep Med 2011, 12(6):591-597.
75. Kohen I., Sarcevic A. Central sleep apnea in a geriatric patient treated with aripiprazole. Am J Ther 2009, 16(2):197-198.
76. Mutschler J., Obermann C., Grosshans M. Quetiapine-induced hyperventilation and dyspnea. Clin Neuropharmacol 2010, 33(4):214.
77. Shelton P.S., Barnett F.L., Krick S.E. Hyperventilation associated with quetiapine. Ann Pharmacother 2000, 34(3):335-337.
78. Jabeen S., Polli S.I., Gerber D.R. Acute respiratory failure with a single dose of quetiapine fumarate. Ann Pharmacother 2006, 40(3):559-562.
79. Freudenmann R.W., Süssmuth S.D., Wolf R.C., et al. Respiratory dysfunction in sleep apnea associated with quetiapine. Pharmacopsychiatry 2008, 41(3):119-121.
80. Kiely J.L., Nolan P., McNicholas W.T. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004, 59(1):50-55.
81. Kheirandish-Gozal L., Gozal D. Intranasal budesonide treatment for children with mild obstructive sleep apnea syndrome. Pediatrics 2008, 122(1):e149-e155.
82. Kheirandish L., Goldbart A.D., Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics 2006, 117(1):e61-e66.
83. Forwand S.A., Landowne M., Follansbee J.N., et al. Effect of acetazolamide on acute mountain sickness. NEngl J Med 1968, 279:839-845.
84. Leaf D.E., Goldfarb D.S. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. JAppl Physiol (1985) 2007, 102:1313-1322.
85. DeBacker W.A., Verbraecken J., Willemen M., et al. Central apnea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med 1995, 151:87-91.
86. Nussbaumer-Ochsner Y., Latshang T.D., Ulrich S., et al. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Chest 2012, 141(1):131-138.
87. Latshang T.D., Nussbaumer-Ochsner Y., Henn R.M., et al. Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial. JAMA 2012, 308(22):2390-2398.
88. Javaheri S., Parker T.J., Wexler L., et al. Effect of theophylline on sleep-disordered breathing in heart failure. NEngl J Med 1996, 335(8):562-567.
89. Oberndorfer S., Saletu B., Gruber G., et al. Theophylline in snoring and sleep-related breathing disorders: sleep laboratory investigations on subjective and objective sleep and awakening quality. Methods Find Exp Clin Pharmacol 2000, 22(4):237-245.
90. Hein H., Behnke G., Jörres R.A., et al. The therapeutic effect of theophylline in mild obstructive sleep Apnea/Hypopnea syndrome: results of repeated measurements with portable recording devices at home. Eur J Med Res 2000, 5(9):391-399.
91. Fischer R., Lang S.M., Leitl M., et al. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 2004, 23(1):47-52.
92. Küpper T.E., Strohl K.P., Hoefer M., et al. Low-dose theophylline reduces symptoms of acute mountain sickness. JTravel Med 2008, 15(5):307-314.
93. Cranston J.M., Crockett A.J., Moss J.R., et al. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, (4). CD001744.
94. Mehta V., Vasu T.S., Phillips B., et al. Obstructive sleep apnea and oxygen therapy: a systematic review of the literature and meta-analysis. JClin Sleep Med 2013, 9(3):271-279.
95. Chowdhuri S., Ghabsha A., Sinha P., et al. Treatment of central sleep apnea in U.S. veterans. JClin Sleep Med 2012, 8(5):555-563.
96. Urquhart D.S., Gulliver T., Williams G., et al. Central sleep-disordered breathing and the effects of oxygen therapy in infants with Prader-Willi syndrome. Arch Dis Child 2013, 98(8):592-595.
97. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disordered breathing among middle-aged adults. NEngl J Med 1993, 328(17):1230-1235.
98. Leech J.A., Onal E., Dulberg C., et al. Acomparison of men and women with occlusive sleep apnea syndrome. Chest 1988, 94(5):983-988.
99. Netzer N.C., Eliasson A.H., Strohl K.P. Women with sleep apnea have lower levels of sex hormones. Sleep Breath 2003, 7(1):25-29.
100. Kapsimalis F., Kryger M.H. Gender and obstructive sleep apnea syndrome, part 1: clinical features. Sleep 2002, 25(4):412-419.
101. Block A.J., Wynne J.W., Boysen P.G., et al. Menopause, medroxyprogesterone and breathing during sleep. Am J Med 1981, 70(3):506-510.
102. Strohl K.P., Hensley M.J., Saunders N.A., et al. Progesteron administration and progressive sleep apneas. JAMA 1981, 145(12):1230-1232.
103. Shahar E., Redline S., Young T., et al. Hormone replacement therapy and sleep-disordered breathing. Am J Respir Crit Care Med 2003, 167(9):1186-1192.
104. Pickett C.K., Regensteiner J.G., Woodard W.D., et al. Progestin and estrogen reduce sleep-disordered breathing in postmenopausal women. JAppl Physiol (1985) 1989, 66(4):1656-1661.
105. Kimura H., Tatsumi K., Kunitomo F., et al. Progesterone therapy for sleep apnea syndrome evaluated by occlusion pressure responses to exogenous loading. Am Rev Respir Dis 1989, 139(5):1198-1206.
106. Cook W.R., Benich J.J., Wooten S.A. Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy. Chest 1989, 96(2):262-266.
107. Rajagopal K.R., Abbrecht P.H., Jabbari B. Effects of medroxyprogesterone acetate in obstructive sleep apnea. Chest 1986, 90(6):815-821.
108. Skatrud J.B., Dempsey J.A., Kaiser D.G. Ventilatory response to medroxyprogesterone acetate in normal subjects: time course and mechanism. JAppl Physiol Respir Environ Exerc Physiol 1978, 44(6):939-944.
109. Zwillich C.W., Sutton F.D., Pierson D.J., et al. Decreased hypoxic ventilatory drive in the obesity-hypoventilation syndrome. Am J Med 1975, 59(3):343-348.
110. D'Ambrosio C., Stachenfeld N.S., Pisani M., et al. Sleep, breathing, and menopause: the effect of fluctuating estrogen and progesterone on sleep and breathing in women. Gend Med 2005, 2(4):238-245.
111. Santamaria J.D., Prior J.C., Fleetham J.A. Reversible reproductive dysfunction in men with obstructive sleep apnoea. Clin Endocrinol (Oxf) 1988, 28(5):461-470.
112. Canguven O., Salepci B., Albayrak S., et al. Is there a correlation between testosterone levels and the severity of the disease in male patients with obstructive sleep apnea?. Arch Ital Urol Androl 2010, 82(4):143-147.
113. Meston N., Davies R.J., Mullins R., et al. Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. JIntern Med 2003, 254(5):447-454.
114. Dexter D.D., Dovre E.J. Obstructive sleep apnea due to endogenous testosterone production in a woman. Mayo Clin Proc 1998, 73(3):246-248.
115. Fogel R.B., Malhotra A., Pillar G., et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. JClin Endocrinol Metab 2001, 86(3):1175-1180.
116. Mokhlesi B., Scoccia B., Mazzone T., et al. Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women. Fertil Steril 2012, 97(3):786-791.
117. Cistulli P.A., Grunstein R.R., Sullivan C.E. Effect of testosterone administration on upper airway collapsibility during sleep. Am J Respir Crit Care Med 1994, 149(2 Pt 1):530-532.
118. Robinson R.W., Zwillich C.W. The effect of drugs on breathing during sleep. Symposium on Sleep Disorders. Clin Chest Med 1985, 6:603-614.
119. Hanafy H.M. Testosterone therapy and obstructive sleep apnea: is there a real connection?. JSex Med 2007, 4(5):1241-1246.
120. Hoyos C.M., Killick R., Yee B.J., et al. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 2012, 77(4):599-607.
121. Stewart D.A., Grunstein R.R., Berthon-Jones M., et al. Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea. Am Rev Respir Dis 1992, 146(6):1389-1393.
122. Kraemer S., Danker-Hopfe H., Pilhatsch M., et al. Effects of supraphysiological doses of levothyroxine on sleep in healthy subjects: a prospective polysomnography study. JThyroid Res 2011, 2011:420580.
123. Davi' M.V., Dalle Carbonare L., Giustina A., et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 2008, 159(5):533-540.
124. Sutherland E.R., Ellison M.C., Kraft M., et al. Elevated serum melatonin is associated with the nocturnal worsening of asthma. JAllergy Clin Immunol 2003, 112(3):513-517.
125. Vardar S.A., Altun G.D., Günerbuyuk C., et al. Melatonin administration acutely decreases the diffusing capacity of carbon monoxide in human lungs. Respiration 2006, 73(4):509-513.
126. Nunes D.M., Mota R.M., Machado M.O., et al. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res 2008, 41(10):926-931.
127. Campos F.L., da Silve-Junior F.P., de Bruin V.M., et al. Melatonin improves sleep in asthma: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2004, 170(9):947-951.
128. Davila D.G., Hurt R.D., Offord K.P., et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994, 150(2):469-474.
129. Hein H., Kirsten D., Jugert C., et al. Nicotine as therapy of obstructive sleep apnea?. Pneumologie 1995, 49(Suppl 1):185-186.
130. Zevin S., Swed E., Cahan C. Clinical effects of locally delivered nicotine in obstructive sleep apnea syndrome. Am J Ther 2003, 10(3):170-175.
131. Taasan V.C., Block A.J., Boysen P.G., et al. Alcohol increases sleep apnea and oxygen desaturation in asymptomatic men. Am J Med 1981, 71(2):240-245.
132. Peppard P.E., Austin D., Brown R.L. Association of alcohol consumption and sleep disordered breathing in men and women. JClin Sleep Med 2007, 3(3):265-270.
133. Mitler M.M., Dawson A., Henriksen S.J., et al. Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. Alcohol Clin Exp Res 1988, 12(6):801-805.
134. Scanlan M.F., Roebuck T., Little P.J., et al. Effect of moderate alcohol upon obstructive sleep apnoea. Eur Respir J 2000, 16(5):909-913.
135. Berry R.B., Bonnet M.H., Light R.W. Effect of ethanol on the arousal response to airway occlusion during sleep in normal subjects. Am Rev Respir Dis 1992, 145(2 Pt 1):445-452.
136. Eckert D.J., Elgar N.J., McEvoy R.D., et al. Alcohol alters sensory processing to respiratory stimuli in healthy men and women during wakefulness. Sleep 2010, 33(10):1389-1395.
137. Wirth K.J., Steinmeyer K., Ruetten H. Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs. Sleep 2013, 36(5):699-708.